Pfizer (NYSE:PFE) announced its intention to sell its entire residual shareholding in Haleon plc, reflecting a divestment ...
Pfizer reportedly offered about 618 million shares through a placement with investors, according to a Wednesday statement.
Pfizer Inc. (PFE) agreed to sell its remaining stake worth $3.3 billion in Haleon PLC (HLN), marking its exit from the UK-based consumer ...
Pfizer has raised £2.5 billion by offloading its remaining 7.3% stake in Haleon, the Panadol and Sensodyne business it used ...
Shares in the consumer health group - originally a joint venture between Pfizer and GSK - are up nearly a fifth since it joined the stock market in 2022.
Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each. The ...
With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...
Pfizer (PFE) stock in focus as the company sells its entire 7.3% stake in Haleon (HLN) for $3.24B. Read more here.
Haleon PLC closed 6.08% below its 52-week high of £4.18, which the company achieved on March 4th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback